[18F]-FBB Neuraceq™

Commercially available: ready to use consumables and optimized method


Florbetaben, a 18F-labelled stilbene derivative, trade name Neuraceq, is a well-known diagnostic pharmaceutical PET tracers approved for clinical use to estimate Aβ plaque density in patients with cognitive impairment (Alzheimer disease (AD) and other cognitive impairments). This radiotracer is increasingly used to evaluate patient eligibility for treatments and for therapy monitoring: accurate diagnosis and early identification of cognitive/functional impairments being indeed key points for patients care and appropriate therapy selections.


The process allows the fully automated production of [18F]-FBB Neuraceq™ using a “Cassette” and a “Reagent kit”.



  • State-of-the-art yield
  • Reduced operator exposure 


Cassette and reagents set up time < 1 min
Synthesis time 52 min
Radiochemical purity [18F]FBB (cis and trans isomers) ≥
93 % at release and ≥ 90 % at expiry
[18F]FBB (cis isomers) ≤ 6 %
[18F]F- ≤ 5 %